trial

Aripiprazole Treatment of the Prodrome

NCTId NCT00169949
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 30
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
30
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-01
Primary completion
—
Eligibility
ALL · 13 Years · 22 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
Bristol-MyersCollaborator

Investigators

1
Barbara A Cornblatt, PhDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

3 sourced
Enrollment
30
Phase
NA
Status
TERMINATED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
Bristol-Myers
company
indication
Prodromal Schizophrenia
indication
Social Adjustment
indication
Prodromal Psychosis
indication
investigator
Barbara A Cornblatt, PhD
person